Piramal Pharma Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
292.83 | 166.01 | 76.4% | 584.83 | -49.93% |
| P/S |
|
2.95 | 18.72 | -84.27% |
|
|
| P/BV |
|
3.28 | 5.84 | -43.73% |
|
|
| P/FCF |
|
117.08 | -123.4 | -194.88% |
|
|
| Ev/Ebitda |
|
0 | 7.87 | -100% |
|
|
| Ev/S |
|
3.78 | 8.85 | -57.27% |
|
|
| Ev/FCF |
|
150.25 | -183 | -182.1% |
|
|
| E/P |
|
0.0034 | 0.0201 | -83.07% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -20.57 | -100% | 0 | 0% |
| ROE |
|
1.12 | 11.34 | -90.11% |
|
|
| ROA |
|
0.5813 | 3.61 | -83.88% |
|
|
| ROIC |
|
0.2589 | 10.04 | -97.42% |
|
|
| ROS |
|
1.01 | -43.43 | -102.33% |
|
|
| ROCE |
|
0 | 6.98 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | 0.2543 | -100% | 0 | 0% |
| Nеt Debt/Ebitda |
|
0 | 0.2026 | -100% |
|
|
| Debt/Ratio |
|
0.3011 | 0.1295 | 132.43% |
|
|
| Debt/Equity |
|
0.9294 | 0.5311 | 75.01% |
|
|
| Debt/Net Income |
|
51.8 | 42.63 | 21.5% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0.13/10
|
0.0508 | 0.3278 | -84.5% | 0.0547 | -7.16% |
| Number of years of dividend growth |
|
2 | 0.9057 | 120.83% | ||
| DSI |
|
1 | 0.8243 | 21.31% |
|
|
| Average dividend growth |
|
21.43 | -27.06 | -179.18% |
|
|
| Average percentage for 5 years |
|
0.0547 | 0.7303 | -92.51% |
|
|
| Average percentage for payments |
|
29.78 | 20.11 | 48.11% |
|
|
| Difference from average difference in sector |
|
-0.277 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
212.48 | 74.64 | 184.67% | ||
| Growth impulse Ebitda in 5 years |
|
0 | 57.29 | -100% | ||
| Growth impulse Net Income in 5 years |
|
-84.05 | 131.15 | -164.09% | ||
| Growth impulse FCF in 5 years |
|
-1074.43 | 62.85 | -1809.51% | ||
| Growth impulse EPS in 5 years |
|
-85.3 | 8.85 | -1063.84% |
IP Score
3.79/10
